Glaukos Co. (NYSE:GKOS) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. lowered its position in Glaukos Co. (NYSE:GKOS - Free Report) by 32.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 383,396 shares of the medical instruments supplier's stock after selling 186,605 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.70% of Glaukos worth $49,949,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Values First Advisors Inc. acquired a new stake in shares of Glaukos in the 3rd quarter worth $25,000. Harvest Fund Management Co. Ltd boosted its holdings in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. GAMMA Investing LLC increased its position in Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after purchasing an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos during the 2nd quarter worth approximately $187,000. Finally, KBC Group NV lifted its holdings in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock valued at $188,000 after buying an additional 201 shares during the period. Hedge funds and other institutional investors own 99.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on GKOS shares. Stifel Nicolaus upped their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock a "buy" rating in a research note on Monday. Truist Financial increased their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. boosted their price target on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Finally, Wells Fargo & Company boosted their target price on Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $136.18.

Glaukos Price Performance

Shares of GKOS traded down $2.57 during trading hours on Thursday, reaching $135.70. 453,746 shares of the company traded hands, compared to its average volume of 569,751. The stock has a fifty day simple moving average of $134.93 and a 200 day simple moving average of $125.51. Glaukos Co. has a fifty-two week low of $59.58 and a fifty-two week high of $146.86. The stock has a market capitalization of $7.48 billion, a PE ratio of -44.93 and a beta of 1.03. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company's quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.50) earnings per share. As a group, research analysts predict that Glaukos Co. will post -1.91 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.